|Year : 2020 | Volume
| Issue : 1 | Page : 116
Prevalence of multiple sclerosis (MS) in Zanjan province of Iran
Mahsa Ghajarzadeh1, Abbas R Foroushani2, Parviz Ghezelbash3, Abdoreza Ghoreishi4, Mehdi Maghbooli5, Mehran Yousefi5, Babak K Rahgoshai5, Farhad G Maemodan5, Mehdi Mohammadifar3, Mohammad A Sahraian6
1 Multiple Sclerosis Research Center, Neuroscience Institute; Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran
2 Department of Epidemiology and Biostatistics, School of Public Health, Tehran, Iran
3 Department of Radiology, Vali-e-asr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
4 Department of Neurology, Vali-e-asr Hospital; School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
5 Department of Neurology, Vali-e-asr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
6 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
|Date of Submission||04-Nov-2019|
|Date of Acceptance||24-Dec-2019|
|Date of Web Publication||06-Aug-2020|
Imam Hospital, Tehran
Source of Support: None, Conflict of Interest: None
Background: The prevalence of multiple sclerosis (MS) varies in different geographical regions and has dramatically increased in Iran. Revealing the high prevalence rate draws the attention of policymakers and helps them allocate necessary resources. The aim of this study is to determine the prevalence of MS in Zanjan province of Iran. Methods: We included all registered residents of Zanjan province with MS on the prevalence day (July 31, 2019). All cases met the McDonald criteria. All registered cases in Zanjan MS society were identified as index cases. Data regarding patient's national code, gender, age, age at the first symptom onset, city of residence, marital status, education level, occupation, ethnicity, family history of MS and the time span between symptom's onset and disease diagnosis were recorded. Results: We identified 758 patients, 551 of whom (72.7%) were female. The mean age at the first symptom onset was 28.9 ±8.7 years old. The crude prevalence was 71.6 per 100,000 population (95% CI 66.6–76.9). The disease was most prevalent in Zanjan city (100.5 per 100,000). The gender-specific prevalence per 100,000 population was 105.4 for women (95% CI: 96.8–114.6) and 38.7 for men (95% CI: 33.6–44.1), with female to male ratio of 2.6. The standardized mortality ratio (SMR) was calculated as expected/observed for both men and women as 2.3 (207/88.2) (551/234.1). Conclusions: Our data confirm that the MS prevalence rate is high in Zanjan province of Iran.
Keywords: Epidemiology, Iran, multiple sclerosis, prevalence
|How to cite this article:|
Ghajarzadeh M, Foroushani AR, Ghezelbash P, Ghoreishi A, Maghbooli M, Yousefi M, Rahgoshai BK, Maemodan FG, Mohammadifar M, Sahraian MA. Prevalence of multiple sclerosis (MS) in Zanjan province of Iran. Int J Prev Med 2020;11:116
|How to cite this URL:|
Ghajarzadeh M, Foroushani AR, Ghezelbash P, Ghoreishi A, Maghbooli M, Yousefi M, Rahgoshai BK, Maemodan FG, Mohammadifar M, Sahraian MA. Prevalence of multiple sclerosis (MS) in Zanjan province of Iran. Int J Prev Med [serial online] 2020 [cited 2021 Jan 24];11:116. Available from: https://www.ijpvmjournal.net/text.asp?2020/11/1/116/291425
| Background|| |
In recent years, studies have shown that the prevalence of multiple sclerosis (MS) has increased in different geographical regions., The prevalence is increasing by growing distance from the equator. Higher prevalence rates have been reported in northern regions of Western Europe, and North America while lower rates have been reported in Asia, the Middle East, and Africa.,,,,,,
Iran is considered as a high-risk country for MS, although it is located in a low-risk geographical area. The distribution of MS is complex and prevalence differs between the areas of similar latitudes as well as within a country. Previous studies estimated point prevalence of MS between 7.4 and 89 per 100000 in different provinces of Iran (using data of Ministry of Health) while all prevalent cases of all provinces were not included.
There is no specific study focusing on the prevalence of MS in the Zanjan province of Iran, although knowing the prevalence of the disease in each province is essential and will help policymakers. So, we designed this study is to determine the prevalence of MS in the Zanjan province of Iran.
| Methods|| |
Zanjan is one of the 31 provinces of Iran which is located in the north-west of the country with a latitude of 36.7° and longitude of 48.5° eastern and an area of 36,400 km2. It has eight cities including Zanjan (the capital city of the province), Abhar, Khorramdarreh, Ijrud, Khodabndeh, Tarom, Mahneshan, and Soltanieh. The total population of the province is 1,057,461 (534,849 male and 522,604 female) based on the census in 2017. It has cold snowy weather and the temperature could be −27° in winter and 32° in summer.
In 2010, the MS Society of Zanjan province was established which is the referral center for the registry of MS cases in the province. All cases were registered by providing a letter from the neurologists based on definite MS diagnosis according to McDonald criteria. All candidates for registration were interviewed by an expert to complete a comprehensive questionnaire while the medical records were reviewed to obtain necessary information. Each year, registered cases were contacted and their state of health was updated.
For the current study, the reference population was all inhabitants of Zanjan province on the prevalence day, July 31, 2019 (total population of the province: 1,057,461).
All registered cases in Zanjan MS society were identified as index cases (n = 960) and duplicate ones according to national numbers, patient's name, and gender were deleted (n = 202).
Finally, 758 cases were enrolled for analysis.
Data regarding patient's national code, gender, age, age at the first symptom onset, city of residence, marital status, education level, occupation, ethnicity, family history of MS, and duration between symptom's onset and disease diagnosis were recorded.
All included cases (n = 758) were evaluated again and their documents were reviewed.
To calculate the standardized mortality ratio (SMR), the number of expected cases was obtained based on the result of the systematic review, which provided the pooled prevalence of MS in the Iranian population. The pooled prevalence rate was 16.5 per 100,000 for men and 44.8 for women. So, the expected number of MS cases calculated as 88.2 for men and 234.1 for women in Zanjan province.
All statistical analyses were performed using STATA (Version 13.0; Stata Corp LP, College Station, TX, USA). Data are presented as mean ± SD for continuous or frequencies for categorical variables. MS prevalence rates per 100,000 persons were calculated. The prevalence rate also was adjusted for age and sex. 95% confidence intervals (95% CIs) were calculated.
| Results|| |
A total of 758 confirmed cases were identified, 551 (72.7%) were female and 207 (27.3%) were male.
Most of them were married (67.5%) and unemployed (76.7%). The ethnicity of 92% was Turk [Table 1].
Ninety-six (12.6%) had a family history of MS and the mean duration of the disease was 10.1 ± 6.7 years.
The mean age at the first symptom onset was 28.9 ± 8.7 years, and in most cases (55.9%) the diagnosis was made during 2 months after symptom onset. The most frequent initial symptom was the weakness of the limbs followed by paresthesia [Table 2].
| Prevalence|| |
The crude prevalence was 71.6 per 100,000 population (95% CI 66.6–76.9), MS was mostly prevalent in Zanjan city (100.5 per 100,000), followed by Khoramdarreh (64.7 per 100,000) and Ijrud (57.3 per 100,000) cities [Table 3].
The gender-specific prevalence per 100,000 population was 105.4 for women (95% CI: 96.8–114.6) and 38.7 for men (95% CI: 33.6–44.1) with female to male ratio of 2.6.
The mean age of all included cases was 39.2 ± 9.4 years on prevalence day which was higher in men (40 ± 9.3 vs 38.7 ± 9.2 years, P = 0.08). The mean age at the first symptom onset was 28.9 ± 8.7 years, while there was no significant difference between two groups (28.5 ± 8.6 in men and 29.8 ± 8.9 in women, P = 0.08).
The prevalence was higher in the 35–44 age group followed by the 45–54 age group [Table 4]. The standardized morbidity ratio (SMR) was calculated as expected/observed for both men and women as 2.3 (207/88.2) (551/234.1).
|Table 4: Age and sex-specific prevalence on prevalence day (July 31, 2019)|
Click here to view
| Discussion|| |
The crude prevalence of MS in the Zanjan province of Iran was estimated as 71.6 per 100,000 population (95% CI 66.6–76.9), which was higher in women than in men (105.4 for women and 38.7 for men). Among all the cities in this province, MS was most prevalent in Zanjan city which is the capital. We also found that the MS prevalence rate was highest in the 35–44-year-old age group, then in the 45–54-year-old age group and decreased with age.
In a previous systematic review conducted in Iran, the pooled prevalence of MS was estimated as 29.3 per 100,000 population. In the same study, the prevalence of MS in Zanjan was reported as 19 per 100,000, which was underestimated,, as the data were based only on the registered patients in Iran's Ministry of Health and Medical Education (MOHME), and it seems that all those registered in Zajan MS society were not included. According to their data, the province in which MS was most prevalent was Isfahan, followed by Tehran (both located in the central part of Iran), and it was least prevalent in Sistan and Baluchestan (located in the southeast of Iran).
In a previous study, estimating MS prevalence in Tehran (capital of Iran) in 2014, the point prevalence was 101.39 per 100,000 population (134.03/100,000 for females and 42.45/100,000 for males), which was higher than that in Zanjan province.
In another study conducted in Torbat Heydarieh (located in the Northeast of Iran), the prevalence of MS was reported as 30.48 in 100,000 population in 2016. In their study, the mean age of patients on the prevalence day was 35 ± 8.5 and F/M ratio was 2.8:1. In the current study, the mean age of patients on the prevalence day was 39.2 and F/M ratio was 2.6.
Izadi et al. assessed the prevalence of MS in the Fars province of Iran. They reported the point prevalence as 72.1/100,000 persons in 2013 (116.5/100,000 in females and 28.3/100,000 in males).
Previously, the latitude of the region was considered as an important factor for MS prevalence and regions closer to the equator (such as Iran) were suggested to have lower prevalence. While this pattern has changed as the prevalence and incidence of MS have increased significantly by increasing the year of studies.
Zanjan, located in the north-west of Iran, has a latitude of 36.7°, which is higher than the latitude of other provinces such as Isfahan, Fars, and Tehran.
The point prevalence of MS is high in Scandinavian countries which have high latitudes. The point prevalence of MS in Finland, Sweden, Denmark, and Norway was reported as 105, 188.9, 173, and 203, respectively.,,,
One of the most important risk factors of MS is vitamin D deficiency, which plays as immune system modulator. A previous study in Iran shows vitamin D deficiency in 39% of MS patients, 38% of their siblings, and 42% of healthy controls. In a study conducted on an adult population in Iran for 12 years, the prevalence of vitamin D deficiency decreased from 30.5 to 24, although insufficiency rates did not change. These findings show that vitamin D deficiency and insufficiency is common in Iran, which predisposes individuals to MS.
Genetics (ethnicity) is another predisposing factor in MS. Although the human leukocyte antigen locus is a powerful predictor of MS, it could not explain all genetic etiology of MS. Vitamin D receptor gene polymorphism has been reported in different studies in MS cases, which has been also present in the Iranian population.
It should be also mentioned that this study had some limitations;First, we did not have the first expanded disability status scale (EDSS) of included cases. Second, during the follow-up, the EDSS values were not registered for cases.
| Conclusions|| |
Our data confirm that MS prevalence is high in the Zanjan province of Iran.
MS: Multiple Sclerosis.
| Declarations|| |
Ethics approval and consent to participate
Consent to publish
We would thank the Zanjan MS society.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Etemadifar M, Maghzi A-H. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler J 2011;17:1022-7.
Ghajarzadeh M, Azizi S, Moghadasi AN, Sahraian MA, Azimi A, Mohammadifar M, et al
. Validity and reliability of the Persian version of the perception de la Scle'rose En Plaques et de ses Pousse'es questionnaire evaluating multiple sclerosis-related quality of life. Int J Prev Med 2016;7:25.
Kurtzke JF. Epidemiologic contributions to multiple sclerosis: An overview. Neurology 1980;30:61-79.
Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler J 2011;17:901-8.
Berg-Hansen P, Moen S, Harbo H, Celius E. High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler J 2014;20:1780-2.
Bentzen J, Meulengracht Flachs E, Stenager E, Brønnum-Hansen H, Koch-Henriksen N. Prevalence of multiple sclerosis in Denmark 1950—2005. Mult Scler J 2010;16:520-5.
Warren S, Svenson L, Warren K. Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler J 2008;14:872-9.
Cheng Q, Miao L, Zhang J, Ding SJ, Liu ZG, Wang X, et al
. A population-based survey of multiple sclerosis in Shanghai, China. Neurology 2007;68:1495-500.
Bhigjee A, Moodley K, Ramkissoon K. Multiple sclerosis in KwaZulu Natal, South Africa: An epidemiological and clinical study. Mult Scler J 2007;13:1095-9.
Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology 2006;27:39-44.
Rosati G. The prevalence of multiple sclerosis in the world: An update. Neurol Sci 2001;22:117-39.
Etemadifar M, Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Nasr Z. Estimated prevalence and incidence of multiple sclerosis in Iran. Eur Neurol 2014;72:370-4.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al
. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
Azami M, YektaKooshali MH, Shohani M, Khorshidi A, Mahmudi L. Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis. PloS One 2019;14:e0214738.
Eskandarieh S, Heydarpour P, Elhami S-R, Sahraian MA. Prevalence and incidence of multiple sclerosis in Tehran, Iran. Iran J Public Health 2017;46:699.
Moghaddam VK, Sarmadi M, Tatari M, Najafi F, Esmaeili A, Hadei M. Epidemiology of multiple sclerosis in Torbat-e Heydarieh (Northeast of Iran) during 1982-2016. Mult Scler Relat Disord 2018;24:184-9.
Izadi S, Nikseresht AR, Poursadeghfard M, Borhanihaghighi A, Heydari ST. Prevalence and incidence of multiple sclerosis in Fars province, Southern Iran. Iran J Med Sci 2015;40:390.
Sarasoja T, Wikström J, Paltamaa J, Hakama M, Sumelahti ML. Occurrence of multiple sclerosis in central Finland: A regional and temporal comparison during 30 years. Acta Neurol Scand 2004;110:331-6.
Eskandari G, Ghajarzadeh M, Yekaninejad MS, Sahraian MA, Gorji R, Rajaei F, et al
. Comparison of serum vitamin D level in multiple sclerosis patients, their siblings, and healthy controls. Iran J Neurol 2015;14:81-5.
Khosravi-Boroujeni H, Sarrafzadegan N, Sadeghi M, Roohafza H, Ng SK, Pourmogaddas A, et al
. Prevalence and trends of vitamin D deficiency among Iranian adults: A longitudinal study from 2001-2013. J Nutr Sci Vitaminol 2017;63:284-90.
Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008;9:516-26.
Abdollahzadeh R, Fard MS, Rahmani F, Moloudi K, Azarnezhad A. Predisposing role of vitamin D receptor (VDR) polymorphisms in the development of multiple sclerosis: A case-control study. J Neurol Sci 2016;367:148-51.
[Table 1], [Table 2], [Table 3], [Table 4]